More Testing Coming for Leading Ebola Vaccines

The Associated Press reported that the World Health Organization (WHO) has said that the two most advanced Ebola vaccines, one from GlaxoSmithKline plc (LSE:GSK) and one from Merck & Co. Inc. (NYSE:MRK) and NewLink Genetics Corp. (NASDAQ:NLNK), seem safe and are set to be tested on healthy volunteers in West Africa.

As quoted in the market news:

The next phase of trials will likely take about six months and manufacturers will ramp up their production at the same time, meaning millions of doses could be available later this year. It’s unclear if that will be quick enough to help slow the epidemic, which appears to be on the decline. So far, Ebola is believed to have sickened more than 20,000 people and killed about 8,000, mostly in Guinea, Liberia and Sierra Leone. Officials estimate the death rate to be about 71 percent.

Click here to read the full report from The Associated Press.